In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates

Journal of Chemotherapy

Volumn 17, Issue 2, 2005, Pages 161-168

  Drago, L ^a   De Vecchi, E ^a   Nicola, L ^a   Legnani, D ^b   Prenna, M ^c   Ripa, S ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Amoxicillin clavulanate; Azithromycin; Clarithromycin; Levofloxacin; Moxifloxacin; Resistance; Streptococcus pneumoniae

Indexed keywords

AGAR; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CLARITHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EXPOSURE; IN VITRO SELECTION; LUNG; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; SPONTANEOUS MUTATION; STREPTOCOCCUS PNEUMONIAE;

EID: 19544387748     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.2.161     Document Type: Article

References (28)

1. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 2004; 50 (Suppl. 1): 3-10.
2. Bozdogan B, Appelbaum PC. Macrolide resistance in Streptococci and Haemophilus influenzas. Clin Lab Med 2004; 24:455-75.
3. Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 2003; 9: 590-599.
4. File TM. Streptococcus pneumonias and community acquired pneumonia: a cause of concern. Am J Med 2004; 117 (Suppl 3A): 39S-50S.
5. Henry M, Leaf HL. Drug-resistant Streptococcus pneumoniae in community acquired pneumonia. Curr Infect Dis Rep 2003; 5: 230-237.
6. Bruinsma N, Kristinsson KG, Bronzwaer S, Schrijnemakers P, Degener J, Tiemersma E, Hryniewicz W, Monen J, Grundmann H. Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumonias in Europe. J Antimicrob Chemother DOI 10.1093/jac/dkh 458. Adv access 5 November 2004.
7. Baquero F. Evolving resistance patterns of Streptococcus pneumonias: a link with long-acting macrolide cosumption? J Chemother 1999; 11, 35-43.
8. Boccia D, Alegiani SS; Pantosti A, Moro ML, Traversa G. The geographic relationship between the use of antimicrobial drugs and the pattern of resistance for Streptococcus pneumoniae in Italy. Eur J Clin Pharmacol 2004; 60:115-119.
9. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimcrob Agents Chemother 1997; 41: 1399-1402.
10. Patel KB, Xuan D. Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40: 2375-2379.
11. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992; 36:1171-1175.
12. Bergogne-Bérézin E. Interpretation of pharmacologic data in respiratory tract infections. Int J Antimicrob Agents 1993; 3: S3-S14.
13. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and Intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119, 1114-22.
14. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44, 835-8.
15. Cook PJ, Andrews JM, Woodcock J, Wise R, Honeybourne D. Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax 1994; 49, 1134-8.
16. National Committee for Clinical Laboratory Standards. (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Sixth Edition M07-A6. NCCLS, Villanova, PA, USA.
17. Michéa Hamzehpour M, Kahr A, Pechère JC. In vitro stepwise selection of resistance to quinolones, ß-lactams and amikacin in nosocomial Gram-negative bacilli. Infection 1994; 22, Suppl. 2, S105-10.
18. Koeth LM, Good CE, Saunders KA, Jakielaszek C. Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin. Int J Antimicrob Agents 2004; 24: 144-149.
19. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. J Antimicrob Chemother 2000; 44: 414-417.
20. Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to five quinolones and amoxicillin-clavulanate In Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 1177-1182.
21. Nagai K, Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 2001; 48: 365-374.
22. Matic V, Kosowska K, Bozdogan B, Kelly LM, Smith K, Ednie LM, Lin G, Credito KL, Clark CL, McGhee P, Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin claritromycin, clindamycin and telithromycin. Antimicrob Agents Chemother 2004; 48: 4103-4112.
23. Drago L, De Vecchi E, Nicola L, Colombo A, Gismondo MR. Selection of resistance of telithromycin against Haemophilus influenzas, Moraxella catarrhalis and streptococci in comparison with macrolides. J Antimicrob Chemother 2004; 54:542-545.
24. Gotfried MH. Comparison of bacteriologic eradication of Streptococcus pneumonias by clarithromycin and reports of increased antimicrobial resistance. Clin Ther 2000; 22: 2-14.
25. Tessier PR, Kim MK, Zhou W, Xuan D, Li C, Ye M, Nightingale CH, Nicolau DP. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002; 46: 1425-1434.
26. Noreddin A, Roberts D, Nichol K, Wierzbowski A, Hoban DJ, Zhanel GG. Pharmacodynamic modelling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumonias simulating clinically achievable serum and epithelial lining fluid free drug concentrations. Antimicrob Agents Chemother 2002; 46: 4029-4034.
27. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolones resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996; 40:2760-2764.
28. Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. Mutations in the 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000; 44: 2118-2125.